SEC Form 10-Q filed by Sorrento Therapeutics Inc.
$SRNE
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/2/2022 | $5.00 | Overweight | Cantor Fitzgerald |
| 8/9/2021 | $30.00 → $26.00 | Buy | HC Wainwright & Co. |
Cantor Fitzgerald initiated coverage of Sorrento Therapeutics with a rating of Overweight and set a new price target of $5.00
HC Wainwright & Co. reiterated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $26.00 from $30.00 previously
B. Riley Securities initiated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $26.00